Organigram Global Inc. filings document the disclosures of a Canadian cannabis company listed on Nasdaq and the TSX. Its Form 6-K reports furnish news releases, material change reports, shareholder meeting materials, proxy forms and other exhibits covering operating results, product announcements, material agreements and corporate events.
The company’s regulatory record includes disclosure about licensed cultivation and processing, adult-use cannabis brands, cannabinoid beverages, the FAST nanoemulsion technology platform, Health Canada regulation, capital-structure matters, shareholder voting, board and committee governance, and director and executive compensation practices.
Organigram Global Inc. (OGI) says its integration of Sanity Group is complete and is adopting a unified global operating model. The company expects annualized run-rate savings of $8 million to $10 million, including approximately $4.5 million to $5.5 million in SG&A and approximately $3.5 million to $4.5 million in operating costs. It expects $5 million to $6 million of savings in fiscal 2027 as changes are phased in, with the full annualized benefit expected in fiscal 2028; one-time integration costs are expected to be $2 million in fiscal 2027. The model centralizes global functions and operations under newly appointed Chief Operating Officer Adrian Frenzel. Organigram also plans to discontinue three brands and trim its remaining SKU assortment in fiscal 2027, concentrating investment on SHRED, BOXHOT and Big Bag O’ Buds. The company says the expected savings depend on successful implementation.
Organigram Global Inc. (OGI) announced its 2026 OG Investor Session will premiere September 30, 2026, at 4:00 p.m. ET on X, with simultaneous streams on LinkedIn and YouTube. The program features presentations from CEO James Yamanaka, CFO Greg Guyatt, and Finn Age Hänsel, President, Rest of World & CSO, a behind-the-scenes look at the company’s Canadian operating footprint, and a management fireside Q&A.
The session is designed around investor questions about future growth, margins, cash generation, and capital allocation. Organigram said a replay will be available afterward on its investor-day webpage.
Organigram Global Inc. (OGI) announced that registration is open for its 2026 OG Investor Session, a digital investor event focused on the company’s global growth strategy. The session will premiere on September 30, 2026 at 4:00 p.m. ET as a video presentation featuring senior leadership, including CEO James Yamanaka, CFO Greg Guyatt and Finn Age Hänsel, President, Rest of World & CSO. The program is expected to cover growth initiatives, strategic priorities, and insights from team members across Organigram’s Canadian and European cannabis operations, followed by a fireside Q&A with investor-submitted questions. Organigram highlights its position as Canada’s #1 cannabis company by market share, its acquisition of Sanity Group GmbH to access the German and broader European medical cannabis markets, and its portfolio of brands and production facilities across multiple Canadian provinces.
Organigram Global Inc. (OGI) reports that it is accelerating the integration of recently acquired Sanity Group GmbH and aligning leadership, operations and market development across a single global platform. Sanity, a leading German medical cannabis player, contributed approximately C$40 million to Organigram’s most recent quarterly consolidated net revenue, representing over 35% of net revenue and being accretive to Adjusted EBITDA.
The German medical cannabis market was valued at more than €2 billion in 2025, serving about 800,000 patients, and is forecast to exceed €4 billion by 2028. Sanity’s quarterly revenue has increased 34% since December 31, 2025 to €25.5 millionFinn Age Hänsel as President, Rest of World & Chief Strategy Officer and Adrian Frenzel as Global Chief Operating Officer, with Tim Emberg continuing as President, Canada.
The company amended the Sanity share purchase agreement, replacing a performance-based earnout of up to €113.8 million with a fixed earnout equal to 85% of the maximum value. The amended structure provides for €20 million in cash and approximately €76 million in Organigram shares, priced using a 20-day VWAP on the TSX with a C$3.00 floor and C$4.00 cap per share, payable between April 1 and May 1, 2027. The transaction is treated as a related party transaction under MI 61-101 but is exempt from formal valuation and minority approval because the fair market value involved is below 25% of Organigram’s C$246,517,467 market capitalization.
Organigram Global Inc. (OGI) is accelerating integration of its acquired German business, Sanity Group GmbH, moving from a standalone structure to a unified global operating model. Sanity contributed approximately CAD$40 million to consolidated net revenue in the most recent quarter, representing over 35% of net revenue, and was accretive to Adjusted EBITDA. Sanity’s quarterly revenue has increased 34% since December 31, 2025 to €25.5 million, underscoring its importance within Organigram’s portfolio.
The company amended the Sanity acquisition agreement, replacing the performance-based earnout with a fixed earnout set at 85% of the original maximum. The earnout will comprise €20 million in cash plus approximately €76 million in Organigram shares, determined using a 20-day VWAP with a floor of C$3.00 and cap of C$4.00 per share. The earnout becomes payable as of April 1, 2027, with payment and share issuance to occur no later than May 1, 2027. New leadership roles were created, including President, Rest of World & Chief Strategy Officer and Global Chief Operating Officer, to drive integration and international expansion across Canada, Germany and other key markets.
Organigram Global Inc. reported strong Q3 Fiscal 2026 results, with net revenue of $105,782, up 49% from Q3 2025, driven mainly by the April acquisition of Germany-based Sanity Group and higher Canadian recreational sales. Gross margin before fair value adjustments improved to 37% of net revenue from 32%, and adjusted EBITDA rose to $13,413 from $5,694.
The company recorded Q3 net income of $105,538, largely due to a $105,783 fair value gain on Preferred Shares linked to British American Tobacco’s investment, rather than core operations. Year-to-date net revenue reached $229,114 (up 28%) and net income $124,586. Cash and short-term investments declined to $11,667 as of June 30, 2026, reflecting the €107.3 million Sanity acquisition and higher working capital, partly funded by a BAT private placement and a new C$60 million credit facility. Management still expects Fiscal 2026 net revenue to exceed $350 million but now guides to modestly negative free cash flow for the year and continues to report a material weakness in internal controls over financial reporting.
Organigram Global Inc. will report earnings results for its third quarter ended June 30, 2026 on Tuesday, August 11, 2026, prior to market open. The company will host a conference call at 8:00 am Eastern Time, with registration and webcast access provided via online links and a replay available within 24 hours for 90 days.
Organigram is described as Canada's #1 cannabis company by market share and a growing global cannabis platform following its acquisition of Sanity Group GmbH. It operates cultivation, processing and edibles facilities in New Brunswick, Quebec, Manitoba and Southwestern Ontario, and markets multiple cannabis brands in Canada and Europe under Health Canada regulation.
Organigram Global Inc., which describes itself as Canada’s #1 cannabis company by market share, provides an update on integration of its recently acquired Sanity Group GmbH and its Canadian market position. Management states that the first quarter including Sanity will begin to show the financial contribution from its international business.
Since closing the acquisition on April 15, 2026, Sanity has maintained an average ~10% market share in Germany, broadly in line with revenue expectations. Recently announced German regulatory changes affecting medical cannabis reimbursement are not expected to be material, as reimbursement-based sales account for about 1% of Sanity’s revenue.
In Canada, Organigram reports leading category positions: 12.5% share in flower, 14.5% in vapes, and 7.3% in pre-rolls, categories that together represent more than 86% of national recreational cannabis retail sales. Overall Canadian recreational market share was 11.1% at the end of June, a 0.4 percentage point decline year-over-year but a 100 basis point increase versus May, helped by gains in beverages and concentrates. The company plans to report Q3 fiscal 2026 results on or about August 11, 2026 and to host a detailed digital investor session in late September.
Organigram Global Inc. reported Q2 Fiscal 2026 net revenue of $59,794, down 9% from Q2 Fiscal 2025 as recreational cannabis sales fell. Gross margin before fair value adjustments declined to 25% and adjusted EBITDA dropped to $870, reflecting weaker product mix and higher returns provisions. The quarter swung to a net loss of $921 versus prior-year net income of $42,456, driven mainly by smaller fair value gains on derivatives and a $5,800 impairment on its U.S. hemp-derived products business.
For the six months ended March 31, 2026, net revenue rose 14% to $123,332, with adjusted gross margin improving to 34% and net income at $19,048. Organigram closed the acquisition of German operator Sanity Group in April 2026 for upfront consideration of €107.3 million and updated Fiscal 2026 guidance, now projecting net revenue to exceed $350 million, with adjusted EBITDA and adjusted gross margin expected to surpass Fiscal 2025 levels and free cash flow around break even. The company highlights strong international expansion, including Germany and Australia, but faces regulatory headwinds for U.S. hemp-derived THC products and continues to remediate a material weakness in internal controls over financial reporting.
Organigram Global Inc. will release its second quarter fiscal 2026 results for the period ended March 31, 2026 on Tuesday, May 12, 2026, prior to market open. The company will hold a conference call that day at 8:00 a.m. Eastern Time, with advance registration required through online links.
Organigram describes itself as a leading Canadian cannabis company focused on high-quality products for adult consumers and international partnerships. It operates cultivation, processing, edibles and fulfillment facilities across multiple Canadian provinces and markets a portfolio of brands including Edison, SHRED, Big Bag O’ Buds and others.